1. Generics Bulletin
  3. >>Strategy

Sandoz Is ‘Not Aiming To Be A Leader’ In US Small-Molecule Generics

North America Chief Keren Haruvi Admits Firm Is ‘Still Suffering’ From Aborted Divestment

 
• By Dave Wallace

In a frank acknowledgement of Sandoz’s position in the US small-molecule generics market, the company’s North America president Keren Haruvi has indicated that the firm is “not looking to be a leader in the generics space” and is still suffering from a lack of investment made in its pipeline during the period several years ago when it was looking to sell the oral solids business.

Yellow paper boat among white paper boats
Sandoz is happy to be just one of many US generics firms • Source: Shutterstock

Sandoz is happy to be just one among many small-molecule generics suppliers in the US market, rather than striving for an all-out leadership position, according to the firm’s North America president Keren Haruvi.

Speaking at the recent Morgan Stanley Healthcare Conference in New York in early September, Haruvi reflected on the dynamics of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business